BR0214705A - Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit - Google Patents
Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kitInfo
- Publication number
- BR0214705A BR0214705A BR0214705-0A BR0214705A BR0214705A BR 0214705 A BR0214705 A BR 0214705A BR 0214705 A BR0214705 A BR 0214705A BR 0214705 A BR0214705 A BR 0214705A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- kit
- prevention
- composition
- neurodegenerative disease
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000004770 neurodegeneration Effects 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0129260.6A GB0129260D0 (en) | 2001-12-06 | 2001-12-06 | Pharmaceutical compositions and their uses |
PCT/GB2002/005542 WO2003047577A2 (en) | 2001-12-06 | 2002-12-06 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0214705A true BR0214705A (pt) | 2004-11-23 |
Family
ID=9927156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0214705-0A BRPI0214705B1 (pt) | 2001-12-06 | 2002-12-06 | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit |
BR0214705-0A BR0214705A (pt) | 2001-12-06 | 2002-12-06 | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0214705-0A BRPI0214705B1 (pt) | 2001-12-06 | 2002-12-06 | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit |
Country Status (24)
Country | Link |
---|---|
US (1) | US7759367B2 (pt) |
EP (1) | EP1465626B1 (pt) |
JP (1) | JP4610898B2 (pt) |
KR (1) | KR100945822B1 (pt) |
CN (1) | CN1738618B (pt) |
AT (1) | ATE406893T1 (pt) |
AU (1) | AU2002347365B2 (pt) |
BR (2) | BRPI0214705B1 (pt) |
CA (1) | CA2469076C (pt) |
CY (1) | CY1108578T1 (pt) |
DE (1) | DE60228761D1 (pt) |
DK (1) | DK1465626T3 (pt) |
ES (1) | ES2311635T3 (pt) |
GB (1) | GB0129260D0 (pt) |
HU (1) | HU228328B1 (pt) |
IL (2) | IL162214A0 (pt) |
MX (1) | MXPA04005376A (pt) |
NO (1) | NO333627B1 (pt) |
NZ (1) | NZ533798A (pt) |
PT (1) | PT1465626E (pt) |
RU (1) | RU2358733C2 (pt) |
SI (1) | SI1465626T1 (pt) |
WO (1) | WO2003047577A2 (pt) |
ZA (1) | ZA200404330B (pt) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177520A1 (en) | 2000-06-12 | 2010-04-21 | Eisai R&D Management Co., Ltd. | 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors |
US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
EP1581539A4 (en) * | 2003-01-03 | 2007-09-19 | Bristol Myers Squibb Co | NEW TYROSINE KINASE HEMMER |
SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
EP1683788B1 (en) * | 2003-11-14 | 2012-03-21 | Shanghai Genomics, Inc. | Derivatives of pyridone and use thereof |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
EP1716150B1 (en) | 2004-01-22 | 2008-04-23 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
CA2562244A1 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
JP2007099781A (ja) * | 2004-07-06 | 2007-04-19 | Eisai R & D Management Co Ltd | 1,2−ジヒドロピリジン化合物の結晶の製造方法 |
MY148809A (en) * | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
EP2592075B1 (en) | 2004-11-02 | 2015-04-29 | Northwestern University | Pyridazine compounds for the treatment of inflammatory diseases |
CA2589102C (en) | 2004-11-02 | 2013-08-13 | Northwestern University | Pyridazine compounds and methods for using the compounds to treat inflammatory diseases |
TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
ATE511843T1 (de) * | 2005-04-04 | 2011-06-15 | Eisai R&D Man Co Ltd | Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz |
JPWO2006109876A1 (ja) * | 2005-04-08 | 2008-11-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不随意運動治療剤 |
EA015252B1 (ru) | 2005-05-10 | 2011-06-30 | Интермьюн, Инк. | Способ модуляции стресс-активированной протеинкиназной системы |
US7786120B2 (en) | 2005-08-29 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
ATE548363T1 (de) | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
US7786130B2 (en) | 2005-08-29 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
JP4865337B2 (ja) * | 2006-01-24 | 2012-02-01 | 富士フイルムファインケミカルズ株式会社 | 2,3’−ビピリジル−6’−オンの製造方法 |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
WO2007126060A1 (ja) * | 2006-04-28 | 2007-11-08 | Eisai R & D Management Co., Ltd | 1,2-ジヒドロピリジン化合物の塩 |
EP2015750A2 (en) | 2006-04-28 | 2009-01-21 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
WO2007127475A2 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Pyridazines for demyelinating diseases and neuropathic pain |
US20090325973A1 (en) | 2006-04-28 | 2009-12-31 | Watterson D Martin | Formulations containing pyridazine compounds |
TW200808763A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
EP1870107A1 (en) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases |
WO2008008493A2 (en) | 2006-07-14 | 2008-01-17 | Amgen Inc. | Alkyne-substituted pyridone compounds and methods of use |
EP2572734B1 (en) | 2006-10-31 | 2016-04-06 | East Carolina University | Cytokine-based fusion proteins for treatment of immune disorders |
WO2008093392A1 (ja) * | 2007-01-29 | 2008-08-07 | Fujifilm Finechemicals Co., Ltd. | 2,3'-ビピリジル-6'-オンの製造方法 |
JP2010520154A (ja) * | 2007-03-05 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患のためのampaレセプターアンタゴニストおよびnmdaレセプターアンタゴニスト |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
EP2148673A1 (en) * | 2007-04-26 | 2010-02-03 | Eisai R&D Management Co., Ltd. | Cinnamide compounds for dementia |
MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
WO2009054544A1 (en) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for parkinson's disease and movement disorders |
WO2009061271A1 (en) | 2007-11-06 | 2009-05-14 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
CA2705834A1 (en) | 2007-11-20 | 2009-05-28 | Merck Sharp & Dohme Corp. | Pyridinone non-nucleoside reverse transcriptase inhibitors |
EP2223912A4 (en) * | 2007-12-21 | 2012-04-25 | Kuraray Co | PROCESS FOR THE PREPARATION OF A 6-HALOGENO-3-ARYLPYRIDINE DERIVATIVE |
US20100256191A1 (en) * | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010040020A1 (en) | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
AU2009309019B2 (en) * | 2008-10-31 | 2014-11-13 | Merck Sharp & Dohme Llc | P2X3, receptor antagonists for treatment of pain |
WO2010054307A1 (en) * | 2008-11-07 | 2010-05-14 | The Cleveland Clinic Foundation | Compounds and methods of promoting oligodendrocyte precursor differentiation |
RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
BRPI0923488A2 (pt) | 2008-12-23 | 2019-09-24 | Hoffmann La Roche | amidas de didropiridona como modulares p2x7 |
US8153808B2 (en) | 2008-12-23 | 2012-04-10 | Roche Palo Alto Llc | Dihydropyridone amides as P2X7 modulators |
EP2382202A1 (en) | 2008-12-23 | 2011-11-02 | F. Hoffmann-La Roche AG | Dihydropyridone amides as p2x7 modulators |
CN102264701A (zh) | 2008-12-23 | 2011-11-30 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮脲 |
KR101381074B1 (ko) | 2008-12-23 | 2014-04-11 | 에프. 호프만-라 로슈 아게 | P2x7 조절제로서의 디히드로피리돈 아미드 |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
AU2010234743A1 (en) | 2009-03-31 | 2011-10-20 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
TW201100398A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted indolo-pyridinone compounds |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
PT2430022E (pt) | 2009-05-12 | 2013-12-26 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas |
EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
EP3964066A1 (en) * | 2009-06-02 | 2022-03-09 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
WO2011039528A1 (en) | 2009-10-02 | 2011-04-07 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
CN102241667B (zh) | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 |
ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
ITMI20111952A1 (it) * | 2011-10-27 | 2013-04-28 | Italiana Sint Spa | Procedimento per la prepazione di 2-metossi-5-(piridin-2-il)piridina, un intermedio del perampanel |
PE20141568A1 (es) * | 2011-10-28 | 2014-11-21 | Neotope Biosciences Ltd | Anticuerpos humanizados que reconocen la alfa-sinucleina |
EP2800747A4 (en) | 2012-01-03 | 2015-12-09 | Mapi Pharma Ltd | POLYMORPHY OF PERAMPANEL |
ITMI20121390A1 (it) | 2012-08-06 | 2014-02-07 | F I S Fabbrica Italiana Sint P A | Procedimento per la preparazione di acido 2-cianofenilboronico e suoi esteri, intermedi del perampanel o di e2040 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
TW201441193A (zh) | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | 吡啶酮化合物 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
EP3063139B1 (en) | 2013-10-29 | 2018-11-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
JP6543633B2 (ja) | 2014-01-29 | 2019-07-10 | ウメクライン コグニション アーベー | 肝性脳症の治療において使用するためのステロイド化合物 |
CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
CN105085382B (zh) * | 2014-05-14 | 2019-10-18 | 江苏豪森药业集团有限公司 | 吡仑帕奈异构体晶型及其制备方法和用途 |
WO2016003536A1 (en) * | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
CN104649963A (zh) * | 2015-01-12 | 2015-05-27 | 苏州莱克施德药业有限公司 | 吡仑帕奈中间体的制备工艺 |
WO2016126085A2 (ko) | 2015-02-04 | 2016-08-11 | 비욘드바이오주식회사 | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 |
EP3259262A4 (en) * | 2015-02-17 | 2018-08-01 | Mapi Pharma Limited | Process and intermediates for the preparation of perampanel |
WO2016147104A1 (en) * | 2015-03-14 | 2016-09-22 | Intas Pharmaceuticals Ltd. | Novel process for the preparation of perampanel and its intermediates thereof |
AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
JP6670922B2 (ja) | 2015-07-08 | 2020-03-25 | チャイナ ナショナル リサーチ インスティテュート オブ フード アンド ファーメンテーション インダストリーズ | Ampa受容体を阻害する活性ペプチド、ならびにその調製方法およびその使用 |
CN106892897A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种羟哌吡酮游离碱新晶型及其制备方法 |
CN106928187A (zh) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | 一种盐酸羟哌吡酮新晶型及其制备方法 |
WO2017127602A1 (en) * | 2016-01-22 | 2017-07-27 | Rush University Medical Center | Identification of novel small molecule beta2 integrin agonists |
EP3251662A1 (en) * | 2016-06-07 | 2017-12-06 | Tolerogenics S.à.r.l. | Matrix-embedded tolerance-promotion adjuvants for subcutaneous immunotherapy |
CN107698498A (zh) * | 2016-08-08 | 2018-02-16 | 罗楹 | 一种羟尼酮的制备方法 |
CN107698499A (zh) * | 2016-08-08 | 2018-02-16 | 罗楹 | 一种羟尼酮的制备方法 |
CN110028442B (zh) * | 2018-01-11 | 2020-07-17 | 新发药业有限公司 | 一种吡仑帕奈的简便制备方法 |
CN108299428B (zh) * | 2018-04-04 | 2019-09-27 | 山东大学 | 8-胺基-7-甲酸甲酯-吡嗪骈吡啶酮衍生物及其制备方法与应用 |
EP3560934A1 (en) | 2018-04-26 | 2019-10-30 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040 |
CN113633708B (zh) * | 2021-09-27 | 2022-02-11 | 重庆希尔安药业有限公司 | 一种稳定的跌打七厘组合物片的制备方法 |
WO2023192491A2 (en) * | 2022-03-30 | 2023-10-05 | Transposon Therapeutics, Inc. | Nucleoside line-1 inhibitors |
CN115403515B (zh) * | 2022-04-25 | 2023-09-08 | 山东达因海洋生物制药股份有限公司 | 吡仑帕奈降解杂质的制备方法及其应用 |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
CN115160217B (zh) * | 2022-08-04 | 2023-09-22 | 山东达因海洋生物制药股份有限公司 | 一种吡仑帕奈的制备方法、合成中间体及降解杂质的制备方法 |
US11958832B1 (en) | 2023-10-12 | 2024-04-16 | King Faisal University | 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5283761A (en) | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | Novel pyridone derivative |
JPS5531072A (en) | 1979-07-30 | 1980-03-05 | Rikagaku Kenkyusho | Preparation of 2-pyridone compound |
CA2356145A1 (en) * | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
ZA952797B (en) | 1994-04-12 | 1996-10-07 | Res Dev Foundation | Method of treating auto-immune diseases using type one interferons |
US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
HU223945B1 (hu) | 1994-09-27 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények |
US5948785A (en) | 1995-04-27 | 1999-09-07 | The Green Cross Corporation | Heterocyclic amide compounds and pharmaceutical use of the same |
WO1997018163A1 (en) | 1995-11-15 | 1997-05-22 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite p1 |
DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
DE69722613T2 (de) | 1996-05-15 | 2004-05-13 | Pfizer Inc. | 2,3,6-trisubstituierte 4(3h)-chinazolinone |
DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
NZ336628A (en) | 1997-02-28 | 2001-03-30 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists |
GB9708945D0 (en) | 1997-05-01 | 1997-06-25 | Merck Sharp & Dohme | Therapeutic agents |
GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
AU1504599A (en) | 1997-12-17 | 1999-07-05 | Shionogi & Co., Ltd. | Novel pyridine compounds |
JP2002519373A (ja) * | 1998-07-02 | 2002-07-02 | エーザイ株式会社 | 製薬組成物及びそれらの使用 |
DE19835918A1 (de) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung |
US6403596B1 (en) * | 1999-06-28 | 2002-06-11 | Merck & Co., Inc. | Substituted pyridones having cytokine inhibitory activity |
EP2177520A1 (en) * | 2000-06-12 | 2010-04-21 | Eisai R&D Management Co., Ltd. | 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors |
CN1203055C (zh) * | 2001-09-26 | 2005-05-25 | 朱德煦 | 治疗或预防细菌感染的方法和组合物 |
JP2004147535A (ja) * | 2002-10-29 | 2004-05-27 | Japan Science & Technology Agency | ギラン・バレー症候群及び/又はフィッシャー症候群発症モデル非ヒト動物 |
-
2001
- 2001-12-06 GB GBGB0129260.6A patent/GB0129260D0/en not_active Ceased
-
2002
- 2002-12-06 PT PT02783299T patent/PT1465626E/pt unknown
- 2002-12-06 KR KR1020047008695A patent/KR100945822B1/ko active IP Right Grant
- 2002-12-06 IL IL16221402A patent/IL162214A0/xx unknown
- 2002-12-06 ES ES02783299T patent/ES2311635T3/es not_active Expired - Lifetime
- 2002-12-06 SI SI200230770T patent/SI1465626T1/sl unknown
- 2002-12-06 JP JP2003548832A patent/JP4610898B2/ja not_active Expired - Fee Related
- 2002-12-06 CA CA2469076A patent/CA2469076C/en not_active Expired - Fee Related
- 2002-12-06 HU HU0402497A patent/HU228328B1/hu not_active IP Right Cessation
- 2002-12-06 BR BRPI0214705-0A patent/BRPI0214705B1/pt unknown
- 2002-12-06 US US10/497,518 patent/US7759367B2/en not_active Expired - Fee Related
- 2002-12-06 NZ NZ533798A patent/NZ533798A/en not_active IP Right Cessation
- 2002-12-06 EP EP02783299A patent/EP1465626B1/en not_active Expired - Lifetime
- 2002-12-06 WO PCT/GB2002/005542 patent/WO2003047577A2/en active IP Right Grant
- 2002-12-06 RU RU2004120538/15A patent/RU2358733C2/ru not_active IP Right Cessation
- 2002-12-06 CN CN028279263A patent/CN1738618B/zh not_active Expired - Fee Related
- 2002-12-06 AU AU2002347365A patent/AU2002347365B2/en not_active Ceased
- 2002-12-06 MX MXPA04005376A patent/MXPA04005376A/es active IP Right Grant
- 2002-12-06 DK DK02783299T patent/DK1465626T3/da active
- 2002-12-06 AT AT02783299T patent/ATE406893T1/de active
- 2002-12-06 DE DE60228761T patent/DE60228761D1/de not_active Expired - Lifetime
- 2002-12-06 BR BR0214705-0A patent/BR0214705A/pt not_active IP Right Cessation
-
2004
- 2004-05-30 IL IL162214A patent/IL162214A/en not_active IP Right Cessation
- 2004-06-02 ZA ZA2004/04330A patent/ZA200404330B/en unknown
- 2004-06-03 NO NO20042298A patent/NO333627B1/no not_active IP Right Cessation
-
2008
- 2008-11-19 CY CY20081101334T patent/CY1108578T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0214705A (pt) | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit | |
DOP2002000429A (es) | Imidazotriazinas | |
BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
BRPI0607017B8 (pt) | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc | |
BR9713363A (pt) | Epotilonas c, d, e e f, preparação e composições | |
BR0111358A (pt) | Compostos de tioacetamida e seu uso | |
WO2000053758A3 (en) | Compositions and methods for the treatment of immune related diseases | |
BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
EP2085096A3 (en) | Novel composition and methods for the treatment of immune related diseases | |
BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
BR0312232A (pt) | Inibidores de caspases e seus usos | |
GB0111186D0 (en) | Novel compounds | |
WO2000073452A3 (en) | Compositions and methods for the treatment of immune related diseases | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
HK1104280A1 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
BRPI0408889A (pt) | uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas | |
BR0115424A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto | |
ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
BR0210910A (pt) | Derivados de imidazotriazinonas e sua aplicação contra processos inflamatórios e/ou doenças imunes | |
WO2003024996A3 (de) | Antibakterielle makrozyklen | |
WO2000015797A3 (en) | Compositions and methods for the treatment of immune related diseases | |
FR2710844B1 (fr) | Composition pour le traitement ou la prévention de l'herpès. | |
DE60220800D1 (de) | Chirales dinapsolin | |
WO2003011309A3 (de) | Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie | |
WO2001066740A3 (en) | Compositions and methods for the treatment of immune related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25C | Requirement related to requested transfer of rights |
Owner name: EISAI CO. LTD. (JP) Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 017080000654/SC DE 29/04/2008, QUEIRA APRESENTAR O DOCUMENTO DE CESSAO LEGALIZADO E NOTORIZADO. |
|
B25B | Requested transfer of rights rejected |
Owner name: EISAI CO. LTD. (JP) Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA, POR FALTA DE CUMPRIMENTO DA EXIGENCIA, PUBLICADA NA RPI 1969 DE 30/09/2008. |
|
B25C | Requirement related to requested transfer of rights |
Owner name: EISAI CO. LTD. (JP) Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 017090000951/SC DE 17/06/2009, REAPRESENTE O DOCUMENTO DE CESSAO COM TRADUCAO JURAMENTADA E A ASSINATURA DE CEDENTE, CESSIONARIO E 2 (DUAS) TESTEMUNHAS, DEVIDAMENTE NOTARIZADO E CONSULARIZADO. |
|
B25B | Requested transfer of rights rejected |
Owner name: EISAI CO. LTD. (JP) Free format text: INDEFERIDA A TRANSFERENCIA REQUERIDA ATRAVES DA PET. NO 017080000654-SC, DE 29/04/2008, PELO NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2082, DE 30/11/2010. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 31/44, A61K 31/443, A61K 31/4433, A61K 31/4436, A61K 31/4439, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/4725, A61K 31/496, A61K 31/501, A61K 31/5377, A61K 3/21, A61K 45/06, A61P 25/00, A61P 25/28 Ipc: A61K 31/44 (2006.01), A61K 31/443 (2006.01), A61K |
|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |